Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
Crinetics Pharmaceuticals (NASDAQ:CRNX) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. ET featuring management discussion of financial results and a business update.
Investors can participate via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with access code 899803, or through a live webcast available on the company's website. Participants are advised to connect 15 minutes before the call, and a webcast replay will be available in the Investor Relations section of www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ:CRNX) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025, dopo la chiusura del mercato. La società terrà una conference call alle 16:30 ET durante la quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento sul business.
Gli investitori potranno partecipare telefonicamente utilizzando i numeri nazionali (1-833-470-1428) o internazionali (1-404-975-4839) con il codice di accesso 899803, oppure seguire la diretta streaming disponibile sul sito web dell'azienda. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell'inizio della chiamata; la registrazione della webcast sarà disponibile nella sezione Investor Relations su www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ:CRNX) ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia a las 4:30 p.m. ET donde la dirección discutirá los resultados financieros y ofrecerá una actualización del negocio.
Los inversores pueden participar por teléfono usando los números nacionales (1-833-470-1428) o internacionales (1-404-975-4839) con el código de acceso 899803, o mediante una transmisión en vivo disponible en el sitio web de la empresa. Se recomienda a los participantes conectarse 15 minutos antes de la llamada; la repetición de la transmisión estará disponible en la sección de Relaciones con Inversionistas en www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ:CRNX)는 2025년 2분기 재무 실적 발표를 2025년 8월 7일 목요일 장 마감 후에 진행할 예정입니다. 회사는 동부시간 오후 4시 30분에 경영진이 재무 실적과 사업 현황에 대해 논의하는 컨퍼런스 콜을 개최합니다.
투자자들은 국내 전화번호(1-833-470-1428) 또는 국제 전화번호(1-404-975-4839)를 통해 접속 코드 899803를 사용하여 참여할 수 있으며, 회사 웹사이트에서 실시간 웹캐스트도 시청할 수 있습니다. 참가자들은 콜 시작 15분 전에 접속할 것을 권장하며, 웹캐스트 녹화는 www.crinetics.com의 투자자 관계 섹션에서 제공됩니다.
Crinetics Pharmaceuticals (NASDAQ:CRNX) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le jeudi 7 août 2025, après la clôture du marché. La société organisera une conférence téléphonique à 16h30 ET au cours de laquelle la direction présentera les résultats financiers et fera un point sur l'activité.
Les investisseurs peuvent participer par téléphone en utilisant les numéros nationaux (1-833-470-1428) ou internationaux (1-404-975-4839) avec le code d'accès 899803, ou via une diffusion en direct disponible sur le site internet de la société. Il est conseillé aux participants de se connecter 15 minutes avant le début de l'appel ; un replay de la diffusion sera disponible dans la section Relations Investisseurs sur www.crinetics.com.
Crinetics Pharmaceuticals (NASDAQ:CRNX) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025 nach Börsenschluss geplant. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, in der das Management die Finanzergebnisse und ein Geschäftsupdate besprechen wird.
Investoren können telefonisch über nationale (1-833-470-1428) oder internationale (1-404-975-4839) Einwahlnummern mit Zugangscode 899803 teilnehmen oder den Live-Webcast auf der Unternehmenswebseite verfolgen. Teilnehmer werden gebeten, sich 15 Minuten vor Beginn der Telefonkonferenz einzuwählen; eine Aufzeichnung des Webcasts wird im Bereich Investor Relations auf www.crinetics.com verfügbar sein.
- None.
- None.
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, August 7 @ 4:30 p.m. ET
| Domestic: | 1 833-470-1428 | |
| International: | 1 404-975-4839 | |
| Access Code: | 899803 | |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) report Q2 2025 earnings?
What time is the Crinetics Pharmaceuticals Q2 2025 earnings call?
How can I access the Crinetics Pharmaceuticals (CRNX) Q2 2025 earnings call?
Where can I find the replay of Crinetics Pharmaceuticals Q2 2025 earnings call?
